Prodrug-Based Nanoreactors with Tumor-Specific in situ Activation for Multisynergistic Cancer Therapy.

Efficient drug delivery into tumor cells while bypassing many biological barriers is still a challenge for cancer therapy. By taking advantage of the palladium (Pd)-mediated in situ activation of a prodrug and the glucose oxidase (GOD)-based β-D-glucose oxidation reaction, we developed a multisynergistic cancer therapeutic platform that combined doxorubicin (DOX)-induced chemotherapy with GOD-mediated cancer orchestrated oxidation therapy and cancer starvation therapy. In the present work, we first synthesized doxorubicin prodrugs (pDOXs) and temporarily assembled them with β-cyclodextrins (β-CDs) to improve their water solubility and reduce their toxic side effects. Then, a nanoreactor was constructed by synthesizing Pd0 nanoparticles in situ within the pores of mesoporous silica nanoparticles (MSNs) for the conversion of pDOX into the active anticancer drug. Furthermore, GOD was introduced to decrease the pH of the tumor microenvironment and induce cancer orchestrated oxidation/starvation therapy by catalyzing β-D-glucose oxidation to form hydrogen peroxide (H2O2) and gluconic acid. Our study provides a new strategy that employs a cascade chemical reaction to achieve combined orchestrated oxidation/starvation/chemotherapy for the synergistic killing of cancer cells and the suppression of tumor growth.

[1]  Ting He,et al.  Glucose Oxidase-Instructed Traceable Self-Oxygenation/Hyperthermia Dually Enhanced Cancer Starvation Therapy , 2020, Theranostics.

[2]  J. Qu,et al.  Biodegradable Manganese-Doped Calcium Phosphate Nanotheranostics for Traceable Cascade Reaction-Enhanced Anti-Tumor Therapy. , 2019, ACS nano.

[3]  Peng R. Chen,et al.  Copper-triggered bioorthogonal cleavage reactions for reversible protein and cell surface modifications. , 2019, Journal of the American Chemical Society.

[4]  Asier Unciti-Broceta,et al.  Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis , 2019, Nature Catalysis.

[5]  Lian-Hua Fu,et al.  Glucose Oxidase‐Instructed Multimodal Synergistic Cancer Therapy , 2019, Advanced materials.

[6]  Tianfu Wang,et al.  Degradable silver-based nanoplatform for synergistic cancer starving-like/metal ion therapy , 2019, Materials Horizons.

[7]  Lian-Hua Fu,et al.  Catalytic chemistry of glucose oxidase in cancer diagnosis and treatment. , 2018, Chemical Society reviews.

[8]  Asier Unciti-Broceta,et al.  Bright insights into palladium-triggered local chemotherapy , 2018, Chemical science.

[9]  C. Vidal,et al.  Concurrent and orthogonal gold(I) and ruthenium(II) catalysis inside living cells , 2018, Nature Communications.

[10]  Liangzhu Feng,et al.  Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy. , 2018, Biomaterials.

[11]  X. Qu,et al.  Designed heterogeneous palladium catalysts for reversible light-controlled bioorthogonal catalysis in living cells , 2018, Nature Communications.

[12]  H. Ran,et al.  Engineering of a Nanosized Biocatalyst for Combined Tumor Starvation and Low-Temperature Photothermal Therapy. , 2018, ACS nano.

[13]  E. W. Meijer,et al.  Catalytically Active Single-Chain Polymeric Nanoparticles: Exploring Their Functions in Complex Biological Media , 2018, Journal of the American Chemical Society.

[14]  P. Pérez,et al.  Discrete Cu(i) complexes for azide–alkyne annulations of small molecules inside mammalian cells† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc04643j , 2018, Chemical science.

[15]  Honggang Cui,et al.  Self-assembling prodrugs. , 2017, Chemical Society reviews.

[16]  Xiaoyuan Chen,et al.  Nanotechnology for Multimodal Synergistic Cancer Therapy. , 2017, Chemical reviews.

[17]  Weijian Chen,et al.  Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy. , 2017, Nano letters.

[18]  Jarkko Rautio,et al.  Prodrugs in medicinal chemistry and enzyme prodrug therapies , 2017, Advanced drug delivery reviews.

[19]  J. Santamaría,et al.  Gold‐Triggered Uncaging Chemistry in Living Systems , 2017, Angewandte Chemie.

[20]  J. Couceiro,et al.  Ruthenium‐Catalyzed Azide–Thioalkyne Cycloadditions in Aqueous Media: A Mild, Orthogonal, and Biocompatible Chemical Ligation , 2017, Angewandte Chemie.

[21]  Miles A. Miller,et al.  Nano-palladium is a cellular catalyst for in vivo chemistry , 2017, Nature Communications.

[22]  Weiping Gao,et al.  Glucose Oxidase-Polymer Nanogels for Synergistic Cancer-Starving and Oxidation Therapy. , 2017, ACS applied materials & interfaces.

[23]  H. Onoe,et al.  In Vivo Gold Complex Catalysis within Live Mice. , 2017, Angewandte Chemie.

[24]  Yi Liu,et al.  Glucose-Responsive Sequential Generation of Hydrogen Peroxide and Nitric Oxide for Synergistic Cancer Starving-Like/Gas Therapy. , 2017, Angewandte Chemie.

[25]  Mark Bradley,et al.  Copper Catalysis in Living Systems and In Situ Drug Synthesis. , 2016, Angewandte Chemie.

[26]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[27]  J. Couceiro,et al.  Transition metal catalysis in the mitochondria of living cells , 2016, Nature Communications.

[28]  Sung Tae Kim,et al.  Supramolecular regulation of bioorthogonal catalysis in cells using nanoparticle-embedded transition metal catalysts. , 2015, Nature chemistry.

[29]  Guo-Feng Luo,et al.  Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles. , 2015, ACS applied materials & interfaces.

[30]  E. Meggers,et al.  Progress towards bioorthogonal catalysis with organometallic compounds. , 2014, Angewandte Chemie.

[31]  Peng R. Chen,et al.  Palladium-triggered deprotection chemistry for protein activation in living cells. , 2014, Nature chemistry.

[32]  John C. Dawson,et al.  Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach , 2014, Nature Communications.

[33]  J. L. M. Cid,et al.  Metal-catalyzed uncaging of DNA-binding agents in living cells , 2014 .

[34]  Cecilia Sahlgren,et al.  Mesoporous silica nanoparticles in medicine--recent advances. , 2013, Advanced drug delivery reviews.

[35]  P. R. Montellano.  Cytochrome P450-activated prodrugs. , 2013 .

[36]  J. Zawilska,et al.  Prodrugs: A challenge for the drug development , 2013, Pharmacological reports : PR.

[37]  T. Graeber,et al.  Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death , 2012, Molecular systems biology.

[38]  Changbong Hyeon,et al.  Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. , 2012, Small.

[39]  Christopher D. Spicer,et al.  Palladium-mediated cell-surface labeling. , 2012, Journal of the American Chemical Society.

[40]  Reyna K. V. Lim,et al.  Copper-free Sonogashira cross-coupling for functionalization of alkyne-encoded proteins in aqueous medium and in bacterial cells. , 2011, Journal of the American Chemical Society.

[41]  Hyesung Jeon,et al.  Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery. , 2011, ACS nano.

[42]  Jianlin Shi,et al.  Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility , 2011 .

[43]  Rahimi M. Yusop,et al.  Palladium-mediated intracellular chemistry. , 2011, Nature chemistry.

[44]  J. Rich,et al.  Reversible derivatization to enhance enzymatic synthesis: Chemoenzymatic synthesis of doxorubicin‐14‐O‐esters , 2008, Biotechnology and bioengineering.

[45]  M. López-Lázaro,et al.  Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. , 2007, Cancer letters.

[46]  E. Meggers,et al.  Ruthenium-induced allylcarbamate cleavage in living cells. , 2006, Angewandte Chemie.

[47]  M. Bradley,et al.  Captured and cross-linked palladium nanoparticles. , 2006, Journal of the American Chemical Society.

[48]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[49]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Nico P E Vermeulen,et al.  Enzyme-Catalyzed Activation of Anticancer Prodrugs , 2004, Pharmacological Reviews.

[51]  M. Vallet‐Regí,et al.  A New Property of MCM-41: Drug Delivery System , 2001 .

[52]  I. Warner,et al.  Complexation of Doxorubicin with β and γ-Cyclodextrins , 1992 .

[53]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.